Below is a comprehensive archive of press releases from MSF-USA. Use the options in the boxes below to filter results based on your preferences.

Country/Region

November 20, 2017

Pfizer does not deserve the patent it was granted in August on its pneumonia vaccine Prevnar13 (PCV13), said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF). MSF is set to argue tomorrow in the High Court of Delhi that it should be overturned because the patent doesn’t meet the standards laid out in India’s Patents Act.

October 13, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières(MSF) filed a petition before the High Court of Delhi today to overturn a patent granted to Pfizer pharmaceutical corporation on the pneumococcal conjugate vaccine (PCV).

August 22, 2017

Hopes for improved access to an affordable pneumococcal conjugate vaccine (PCV) that protects both children and adults from pneumonia was dealt a major blow after the Indian patent office granted a patent to the U.S. pharmaceutical corporation Pfizer.

June 26, 2017

As U.S. President Donald Trump and Indian Prime Minister Narendra Modi meet at the White House today, Doctors Without Borders/Médecins Sans Frontières (MSF) warned that U.S. pressure on India to change its drug regulatory and patent system could result in millions of people in the U.S. and around the world losing their lifeline of affordable medicines. As an international medical humanitarian organization that relies on affordable generic medicines produced in India to run its medical programs in more than 60 countries, MSF urged Modi to stand strong and protect India’s role as the “pharmacy of the developing world.”

February 14, 2017

NEW YORK/NEW DELHI, FEBRUARY 14, 2017—Five new challenges against flawed patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir, and increase access for millions of people.

June 09, 2016

UN governments adopted a Political Declaration on Ending AIDS during the UN’s High-Level Meeting on Ending AIDS in New York on June 8, 2016, in which governments have committed to reaching 30 million people with HIV treatment by 2020.

June 02, 2016

India must resist pressure from US lawmakers and pharmaceutical industry groups to block access to key medicines for millions of people worldwide

May 10, 2016

Gilead Sciences has been seeking patents in India for the hepatitis C drug sofosbuvir. The patent applications have been challenged by groups of people living with hepatitis C and HIV through "pre-grant oppositions." The patent just granted by India’s patent office was initially rejected in January 2015, just before President Obama’s visit to India, which was seen as vexing the US. Gilead appealed the rejection and the patent has now been granted.

April 21, 2016

In advance of the next round of the Regional Comprehensive Economic Partnership (RCEP) negotiations starting in Perth, Australia, this Sunday, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is warning that current proposals in this trade agreement could severely restrict access to affordable medicines for millions of people around the world. Text from a leaked chapter on intellectual property shows that Japan and South Korea have made proposals that go beyond what international trade rules require, undermining access to affordable generic medicines and making it harder for patients and treatment providers like MSF to access affordable, lifesaving medicines.

March 29, 2016

MSF urges Indian Prime Minister not to cave into pressure from EU to accept trade deal that could prevent millions of people from accessing lifesaving medicines

Pages